Arvinas, Inc. (NASDAQ: ARVN) is a Healthcare company (Biotechnology) with a market capitalization of $447M. The Maz Rating grades it against the other companies in its sector.
Arvinas, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.82, Arvinas, Inc. trades at 1.6x sales and 0.8x book value. Over the last twelve months it generated about $284M of revenue and a net loss of $10M. It runs a gross margin of 95.9%, an operating margin of -10.7% and a net margin of -3.5%. It shows return on equity of -2.0%, return on invested capital of -5.4% and a free cash flow yield of -36.5%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 8.39. Over the past 52 weeks the share price ranged from $6.33 to $14.51, with a beta of 1.80.
Arvinas, Inc. does not currently pay a dividend.
26 Wall Street analyst ratings cover the stock: 19 Buy, 6 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Arvinas, Inc. (ARVN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.08% / 30% · (Cash+Inv) / Mkt Cap (36m) 108.1% / 30% · Interest income / Revenue 1080.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.08% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 108.1% / 33% · Receivables / Mkt Cap (36m) 1.03% / 49% · Interest income / Revenue 1080.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.08% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 108.1% / 33.33% · Receivables / Mkt Cap (24m) 1.03% / 33.33% · Interest income / Revenue 1080.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.06% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 91.6% / 33.33% · Receivables / Avg Assets (4Q) 2.73% / 33.33% · Interest income / Revenue 1080.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.07% / 33.33% · (Cash+ST Inv) / Total Assets 91.9% / 33.33% · (Cash+Recv) / Total Assets 92.8% / 33.33% · Interest income / Revenue 1080.0% / 5% | Fail |
No. As of September 2026, Arvinas, Inc. (ARVN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Arvinas, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 1080.0% of each dividend: Arvinas, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.